Transcription of the brain creatine kinase gene in glial cells is modulated by cyclic AMP-dependent protein kinase.
The brain creatine kinase (CKB) gene is expressed in a variety of tissues with highest expression seen in the brain. We have previously shown in primary rat brain cell cultures that CKB mRNA levels are high in oligodendrocytes and astrocytes and low in neurons (Molloy et al.: J Neurochem 59:1925-1932, 1992). In this report we show that treatment of human U87 glioblastoma cells with forskolin and IBMX, to elevate intracellular cAMP, induces expression of CKB mRNA from the transiently transfected rat CKB gene by 14-fold and also increases expression from the endogenous human CKB gene. This induction of CKB mRNA i) is due to increased transcription; ii) occurs rapidly (with maximal induction after 6 hr; iii) requires the activity of protein kinase A (PKA), but iv) does not require de novo protein synthesis and, in fact, is superinduced in the presence of cycloheximide. Given the role of oligodendrocytes in the energy-demanding process of myelination and of astrocytes in ion transport, these results have physiological significance, since they suggest that changes in cellular energy requirements in the brain during events, such as glial cell differentiation and increased neuronal activity, may in part be met by a cAMP-mediated modulation of CKB gene expression. Of particular importance is the possible modulation of CKB gene expression during myelinogenesis, since oligodendrocyte differentiation has been shown previously to be stimulated by increases in cAMP.
Kuzhikandathil
E V
EV
Department of Biological Sciences, University of Delaware, Newark 19716.
Molloy
G R
GR
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000201:enzymology*; D001932:Brain Neoplasms / Q000473:pathology; D003001:Cloning, Molecular; D005576:Colforsin / Q000031:analogs & derivatives / Q000494:pharmacology; D003402:Creatine Kinase / Q000096:biosynthesis* / Q000235:genetics; D000242:Cyclic AMP / Q000502:physiology; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000502:physiology*; D004734:Energy Metabolism; D004789:Enzyme Activation / Q000187:drug effects; D004790:Enzyme Induction / Q000187:drug effects; D005909:Glioblastoma / Q000473:pathology; D005910:Glioma / Q000473:pathology; D006367:HeLa Cells / Q000187:drug effects; D006801:Humans; D007527:Isoenzymes; D007546:Isoquinolines / Q000494:pharmacology; D009186:Myelin Sheath / Q000502:physiology; D009419:Nerve Tissue Proteins / Q000096:biosynthesis* / Q000235:genetics; D009457:Neuroglia / Q000187:drug effects / Q000201:enzymology*; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D016372:RNA, Antisense / Q000494:pharmacology; D051381:Rats; D011993:Recombinant Fusion Proteins / Q000096:biosynthesis; D013449:Sulfonamides; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection; D014407:Tumor Cells, Cultured
D007527:Isoenzymes; D007546:Isoquinolines; D009419:Nerve Tissue Proteins; D011500:Protein Synthesis Inhibitors; D016372:RNA, Antisense; D011993:Recombinant Fusion Proteins; D013449:Sulfonamides; D005576:Colforsin; D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D003402:Creatine Kinase; D000262:Adenylyl Cyclases; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide; C047983:1,9-dideoxyforskolin; D015056:1-Methyl-3-isobutylxanthine